Novozymes Biopharma will be showcasing its pioneering Bacillus-based Hyaluronic Acid (bHA) at the 2010 International Conference on Hyaluronan. The company will also launch its first pilot cGMP compliant sample program for this novel source of HA and will be delivering a series of informative, educational presentations.

Novozymes Biopharma’s booth will feature a recombinant source of HA, produced without the use of animal-derived raw materials or organic solvents. This innovative approach to producing HA product is based on Novozymes Biopharma’s patented, safe fermentation and purification technology which results in a consistent and pure product. The production system is based on Bacillus subtilis, a well-characterized, non-pathogenic and endotoxin-free organism that is considered safe by the US Food and Drug Administration (FDA).

In addition to providing a ‘hands-on’ demonstration area of Hyaluronic Acid, Novozymes Biopharma will also be providing bHA pilot samples ahead of the launch of the company’s new state-of-the-art Q7 cGMP compliant HA facility in Tianjin, China. This new facility is due to come on line in Q1, 2011 and will be dedicated to the production of HA for medical applications.